|
|||||
|
|
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison |
|
| Authors: | Philip D. Home DM Vanita R. Aroda MD Lawrence Blonde MD Patricia Guyot PhD Alka Shaunik MD Mir Sohail Fazeli MD Hardik Goswami PhD Sanjay Kalra DM Mir-Masoud Pourrahmat BSc |
| Affiliation: | 1. Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK;2. Brigham and Women's Hospital, Boston, Massachusetts, USA;3. Department of Endocrinology, Ochsner Medical Center, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, New Orleans, Louisiana, USA;4. Sanofi, Bridgewater, New Jersey, USA;5. Sanofi, Bridgewater, New Jersey, USA At time study was conducted.;6. Doctor Evidence, Santa Monica, California, USA Evidinno Outcomes Research Inc., Vancouver, British Columbia, Canada;7. Department of Endocrinology, Bharti Hospital, Karnal, India |
| Abstract: | |
| Keywords: | blood glucose fixed-ratio combination glucagon-like peptide-1 receptor agonist hypoglycaemia indirect treatment comparison systematic review |